These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 19191052)

  • 21. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
    Alagona P
    Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
    Kones R
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The JUPITER trial: How will it change clinical practice?
    Watson KE
    Rev Cardiovasc Med; 2009; 10(2):91-6. PubMed ID: 19593321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An evaluation of educational outreach to improve evidence-based prescribing in Medicaid: a cautionary tale.
    Zillich AJ; Ackermann RT; Stump TE; Ambuehl RJ; Downs SM; Holmes AM; Katz B; Inui TS
    J Eval Clin Pract; 2008 Oct; 14(5):854-60. PubMed ID: 19018918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Statins, cardiovascular disease, and drug safety.
    Gotto AM
    Am J Cardiol; 2006 Apr; 97(8A):3C-5C. PubMed ID: 16581326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A peri-operative statin update for non-cardiac surgery. Part II: Statin therapy for vascular surgery and peri-operative statin trial design.
    Biccard BM
    Anaesthesia; 2008 Feb; 63(2):162-71. PubMed ID: 18211448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
    Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
    Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of statin adherence on cerebrovascular disease in primary prevention.
    Perreault S; Ellia L; Dragomir A; Côté R; Blais L; Bérard A; Lalonde L
    Am J Med; 2009 Jul; 122(7):647-55. PubMed ID: 19559167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of coronary calcium screening versus broad statin therapy for patients at intermediate cardiovascular risk.
    Sniderman AD; Thanassoulis G; Lawler PR; Williams K; Furberg CD
    Am J Cardiol; 2012 Aug; 110(4):530-3. PubMed ID: 22579082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Questioning the "beatification" of statins.
    Mascitelli L; Pezzetta F
    Int J Cardiol; 2008 Jan; 123(2):197-8. PubMed ID: 17320217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of hyperlipidemia in older adults.
    Alexander KP; Blazing MA; Rosenson RS; Hazard E; Aronow WS; Smith SC; Ohman EM
    J Cardiovasc Pharmacol Ther; 2009 Mar; 14(1):49-58. PubMed ID: 19124599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
    Teoh H; Mendelsohn AA; Goodman SG; Jaffer S; Chen RY; Tjia S; Theriault L; Langer A; Leiter LA;
    Am J Cardiol; 2009 Sep; 104(6):798-804. PubMed ID: 19733714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of statin drugs in the management of the peripheral vascular patient.
    Samson RH
    Vasc Endovascular Surg; 2008; 42(4):352-66. PubMed ID: 18621887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discordance between physicians' estimation of patient cardiovascular risk and use of evidence-based medical therapy.
    Tsang JL; Mendelsohn A; Tan MK; Hackam DG; Leiter LA; Fitchett D; Lin PJ; Grima E; Langer A; Goodman SG;
    Am J Cardiol; 2008 Nov; 102(9):1142-5. PubMed ID: 18940280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis.
    Harper CR; Jacobson TA
    Curr Opin Lipidol; 2007 Aug; 18(4):401-8. PubMed ID: 17620856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry.
    Kumar A; Fonarow GC; Eagle KA; Hirsch AT; Califf RM; Alberts MJ; Boden WE; Steg PG; Shao M; Bhatt DL; Cannon CP;
    Crit Pathw Cardiol; 2009 Sep; 8(3):104-11. PubMed ID: 19726929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statins in acute coronary syndromes: do the guideline recommendations match the evidence?
    Morrissey RP; Diamond GA; Kaul S
    J Am Coll Cardiol; 2009 Oct; 54(15):1425-33. PubMed ID: 19796735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 'Muscle-sparing' statins: preclinical profiles and future clinical use.
    Pfefferkorn JA
    Curr Opin Investig Drugs; 2009 Mar; 10(3):245-52. PubMed ID: 19333882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statins and the risk of new-onset diabetes: a review of recent evidence.
    Preiss D; Sattar N
    Curr Opin Lipidol; 2011 Dec; 22(6):460-6. PubMed ID: 21897230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuromuscular complications of statins.
    Ahn SC
    Phys Med Rehabil Clin N Am; 2008 Feb; 19(1):47-59, vi. PubMed ID: 18194749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.